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Background: To apply and evaluate various equations for estimated glomerular filtration
rates (eGFR) in a large paediatric type 1 diabetes population and compare the eGFR
values with urinary creatinine clearances (UCC) in a subset of patients.
Methods: Six eGFR formulae applicable for children and adolescents were used
for calculation of eGFR values in 36,782 children/adolescents with type 1 diabetes.
Via regression models, factors influencing eGFR values were identified. eGFR values
were compared with measured UCC in 549 patients. Spearman correlation coefficients
were given to assess the relation of eGFR and UCC values. Bland-Altman-Plots with
corresponding linear regression were drawn to evaluate the agreement between eGFR
and UCC.
Results: eGFR values differed widely depending on the formula used, resulting in
a percentage of pathological values <60 mL/min/1.73 m2 up to 8%. Regression
models showed age, sex, and duration of diabetes as influencing factors.
Microalbuminuria was associated with significantly higher eGFR values for all
formulae. In comparison of eGFR with UCC, the highest correlation coefficient
was 0.33, the lowest 0.01. Bland-Altman-Plots demonstrated graphically a
poor agreement between eGFR and UCC, regardless of the formula used.
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Boettcher et al. eGFR in Type-1-Diabetes Children
Conclusions: The broad range of eGFR values indicate that an ideal eGFR formula
for children and adolescence with T1D is yet missing. The minimal agreement between
measured UCC and eGFR values urges us to be careful in application and interpretation
of eGFR values regardless of the formula used.
Keywords: diabetic kidney disease, estimated glomerular filtration rate, type 1 diabetes, children and adolescents,
urinary creatinine clearance
INTRODUCTION
Diabetic nephropathy remains a common complication in
patients with diabetes; the prevalence of diabetic nephropathy
in individuals with diabetes younger than 18 years of age is
estimated to be 3.44% in the United States (1). Diabetes is
the main cause of end-stage renal disease (ESRD), with type
1 patients facing a 30-year cumulative incidence for ESRD
of 3.3–7.8% (2). Identifying and monitoring diabetic kidney
disease requires inter alia assessment of kidney function. This
can be done by determining the glomerular filtration rate
(GFR). As the measurement of GFR using the clearance of
exogenous substances such as inulin is cumbersome, serum
creatinine concentration combined with other easily determined
parameters (height, weight, sex, etc.) is most frequently used for
estimating GFR (eGFR) and is recommended by the American
Diabetes Association and International Society of Nephrology
(3, 4). In paediatrics still in use as a screening method for
renal disease are timed urinary creatinine clearances—despite the
known main limitation of incomplete urine collections—as it is a
non-invasive tool.
Many eGFR-equations that are in use today were originally
designed for adults and therefore less suitable for children, as
proven in numerous studies (5–8). However, over the last 15 years
a whole string of equations (based on serum creatinine) more
appropriate or even designed for children were published (9–12).
In this study, we aimed to give an overview of GFR estimated
by various newer and older formulae in children and adolescents
with type 1 diabetes (T1D), to identify influencing factors and
to compare eGFR values obtained with different formulae with
creatinine clearance based on timed urine collections (UCC).
METHODS
Data Source
The German-Austrian-Swiss-Luxembourgish DPV (Diabetes-
Patienten-Verlaufsdokumentation) Initiative database comprises
prospective data of 485 diabetes centres. Demographic,
anthropometric, and diabetes-related characteristics are
documented for quality assurance and scientific research. The
institutional review board of Ulm University and the local
institutional review boards approved analysis of anonymised
DPV data.
Study Population
A total number of 36,782 patients with T1D out of 365 paediatric
diabetes centres were identified in the DPV database according to
the following criteria: age 1–<18 years, serum creatinine value,
height and weight data available, and time period 2010–2018.
Variables
Demographic variables of our study group included age, sex, and
duration of diabetes. The variable age was categorised as 1–<6, 6–
<12, and 12–<18 years. Height and weight were used to calculate
the BMI (weight [kg]/height [m2]) and the respective BMI-SD
scores (categorised as <90th percentile, ≥90–97th percentile,
and ≥97th percentile) as a measure of overweight and obesity
according to recent reference data (13). Systolic and diastolic
blood pressure resulted in a diagnosis of “hypertension” (>95th
percentile of age specific reference values) (14). Antihypertensive
medication was documented. Glycaemic control was assessed
by HbA1c levels. In order to equalise for different laboratory
methods, HbA1c data were mathematically standardised to the
DCCT reference range (4.05–6.05% [20.8–42.6 mmol/mol])
(15) and classified into three categories: HbA1c <7.5% [<58.5
mmol/mol], 7.5–< 9.0% [58.5–74.9 mmol/mol], and ≥ 9.0%
[≥74.9 mmol/mol]. IDMS traceable serum creatinine values
served for calculation of eGFR, using different GFR estimation
formulae: four formulae developed especially for use in children
(IDMS-traceable formula by Schwartz [eGFR_Schwartz_short],
Schwartz-Lyon-formula [eGFR_SchL], Full-age-spectrum with
Q-age extension [eGFR_FAS_QA], Full-age-specrum with Q-
height extension [eGFR_FAS_QH], as well as two formulae
originally designed for adults (Lund-Malmö [eGFR_LM], Lund-
Malmö with lean body mass [eGFR_LM_LBM]) (Table 1). When
available, a measured urinary Creatinine Clearance (UCC)—
via timed urine collection and concomitant blood sample—
was documented. UCC –values below 50 mL/min/1.73 m2 were
excluded. Microalbuminuria, defined as at least two positive
urine albumin tests out of three consecutive tests (random
spot collection) and diabetic retinopathy (ophthalmological
diagnosis) were registered. For each patient, data of the most
recent year of follow-up were analysed.
Statistical Analysis
For descriptive analysis, mean, SD (continuous variables),
median with lower and upper quartile and percentages
(categorical variables) were provided. Kruskal-Wallis-tests
(continuous variables) and χ2-tests (binary variables) were
applied for group comparisons. P values were adjusted according
to Holm (Bonferroni-stepdown) for multiple comparisons. To
investigate the effect of potentially influencing factors on the
eGFR, linear regression models were used. F tests were deployed
to test for differences between groups; adjusted means (least
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TABLE 1 | eGFR formulae used in this study.
Name Formula
IDMS-traceable “Short” Schwartz
(eGFR_Schwartz_Short) (9)
= 41.3 * (height [m]/serum creatinine [mg
dL
]
Schwartz-Lyon (eGFR_SchL) (10) = k* (height [m]/serum creatinine [mg
dL
]
with k = 41.3 for boys >13 years of age and k = 36.7 for all others
Full-age-spectrum with Q-age extension
(eGFR_FAS_QA) (11)
= 107.3/serum creatinine [mg
dl
]/Q [mg
dL
]
with Q = 0.21+ 0.057 * age (years) − 0.0075 * age2 + 0.00064 * age3 − 0.000016 * age4 for boys
with Q = 0.23+ 0.034 * age (years) − 0.0018 * age2 + 0.00017 * age3 − 0.0000051 * age4 for girls
Full-age-spectrum with Q-height extension
(eGFR_FAS_QH) (11)
= 107.3/serumcreatinine [mg
dl
]/Q [mg
dL
]
with Q = 3.94− 13.4 * height [m]+ 17.6 * height2 − 9.84 * height3 + 2.04 * height4
Lund-Malmö (eGFR_LM) (12) = eZ−0.0124*age [years]+0.339* ln (age) if male
= eZ−0.0124*age [years]+0.339* ln (age)−0.226 if female
with e = the base of the natural logarithm (ln)
and Z = 4.62− 0.00112 * serum creatinine [mg
dL
] if serum creatinine < 150 µmol/L
Z = 8.17+ 0.0005 * serum creatinine− 1.07 * ln (serum creatinine) [mg
dL
]) if serum creatinine ≥ 150 µmol/L
Lund-Malmö with lean body mass
(eGFR_LM_LBM) (12)
= eZ−0.00587*age [years]+0.00977*LBM
with e = the base of the natural logarithm (ln)
and Z = 4.95− 0.0110 * serum creatinine [mg
dL
] if serum creatinine < 150 µmol/L
Z = 8.58+ 0.0005 * serum creatinine− 1.08 * ln (serum creatinine)[mg
dL
]) if serum
creatinine ≥ 150 µmol/L
with lean body mass (LBM) = 1.07 * weight [kilogramm]− 148 * (weight/height [ m])2
Measured creatinine Clearance (16) (UCC) = (urinary creatinine
[
mg
dL
]
* urine volume [ml] /(serum creatinine
[
mg
dL
]
* time [min]) * 1.73/BSA
squared means) were calculated based on observed marginal
frequencies. Spearman correlation was used to assess the relation
of eGFR values obtained with different formulae and UCC
values. Bland-Altman-Plots with corresponding linear regression
were utilized to evaluate the agreement between eGFR and UCC.
All analyses were performed with the SAS for Windows version
9.4 software (SAS Institute, Cary, NC, USA).
RESULTS
Characterisation of Study Cohort
Of a total of 54,393 children and adolescents aged 1–<18
years with T1D followed in the DPV database, 36,782 had a
documented serum creatinine value and complete auxological
data, of whom 549 patients with a 24-h urine /blood sample for
the calculation of UCC. Of the final study population, 46.6% (n
= 17,146) were female. Mean age was 14.0± 3.8, median age 15.4
[11.7 lower Quartile-−17.3 upper Quartile] years with 5.0% of the
patients <6 years (mean 4.2 ± 1.3, median 4.4 [3.2–5.3] years),
21.4% between 6 and <12 years (mean 9.5 ± 1.7, median 9.7
[8.1–10.9] years), and 73.6% >12 years of age (mean 16.0 ±1.7,
median 16.8 [14.8–17.4] years). Average duration of diabetes was
5.5 ± 4.2 years. Overall, 40.8% of the children/adolescents had
an HbA1c value <7.5, 36.8% between 7.5 and 9%, and 22.4 ≥
9%. Mean serum creatinine was 0.42 ± 0.15 mg/dl in the age
group < 6 years, 0.55± 0.15 mg/dl in the age group 6–<12 years
and 0.74 ± 0.18 mg/dl in the age group 12–18 years; mean BMI-
SDS was 0.28 ± 0.94. Of the population that was screened for
diabetic complications, 0.5% showed diabetic retinopathy, 7.0%
microalbuminuria (age group <6 years 2.7%, age group 6–<12
years 5.2%, 12–<18 years 7.7%), 20.7% fulfilled the criteria for
“hypertension” and 2.6% took antihypertensive medication.
GFR Estimated via Different Formulae and
Influencing Factors
Table 2 gives an overview of eGFR, calculated by six different
formulae, and UCC. Presented are mean eGFR values for the
whole population and for subgroups according to sex, age,
and BMI. The percentages of eGFR-values < 60 ml/min/1.73
m2 are included. Mean eGFR ranged between 95.3 ± 16.0
mL/min/1.73 m2 (eGFR_LM) and 110.4 ± 26.0 mL/min/1.73
m2 (eGFR_FAS_QH) in all patients, with the results of the
Schwartz_Short-formula being in between the two extremes
(102.8± 24.1 mL/min/1.73 m2). For females, the lowest [highest]
mean eGFR was seen when calculated by the eGFR_LM-Formula
(88.1 ± 11.9 mL/min/1.73 m2) [eGFR_FAS_QH (109.6 ± 25.3
mL/min/1.73 m2)]; for males, the calculation via SchwL-formula
showed the lowest (95.3 ± 21.1 mL/min/1.73 m2), and the
calculation via FAS-QH the highest (111.1 ± 26.6) mean eGRF.
In the age group 1–<6 years mean eGFR varied betweenminimal
93.4 ± 17.6 (eGFR_LM) and 114.2 ± 33.1 mL/min/1.73 m2
(eGFR_Schwartz_Short), in the age group 6–<12 between 98.6
± 22.0 (eGFR_SchwL) and 111.0 ± 24.7 mL/min/1.73 m2
(eGFR Schwartz_short), and in the age group 12–<18 between
93.6 ± 15.2 (eGFR_LM) and 112.2 ± 26.1 mL/min/1.73 m2
(eGFR_FAS_QH). Regarding the BMI-subgroups, the BMI group
≥ 97 P showed the highest variation for mean eGFR: 94.6± 15.5
(eGFR_LM)−116.1± 17.2 mL/min/1.73 m2 (eGFR_LM_LBM).
Linear regression analyses adjusted for age, sex, duration of
diabetes and BMI, identified age for all formulae (Figure 1A) and
sex for all but the Schwartz-Lyon formula as significant
influencing factors. Diabetes duration seemed to affect
Schwartz-short-, Schwartz-Lyon-, FAS-QA-, Lund-Malmö-, and
Lund-Malmö-LBM-formulae. Introducing microalbuminuria or
diabetic retinopathy into the regression models (adjusted for age,
sex, duration of diabetes, BMI, HbA1c, antihypertensive drugs)
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TABLE 2 | eGFR values (ml/min/1.73 m2) and UCC in all patients and subgroups according to gender, age, and BMI as well as percentages of eGFR values < 60 ml/min/1.73 m2; unadjusted comparison female to
male group: ***p < 0.0001; unadjusted comparison age group 1–<6 and age group 6–<12: p < 0.0001, p < 0.001, p < 0.05; unadjusted comparison age group 6–<12 and age group 12–<18: p <
0.0001; unadjusted comparison age group 1–<6 and age group 12–<18: p < 0.0001; unadjusted comparison BMI group <P90 and BMI group ≥ P90–97: p < 0.0001; unadjusted comparison BMI group
≥ P90–97 and BMI group ≥ P97: p < 0.0001, p < 0.05; unadjusted comparison BMI group < P90 and BMI group ≥ P97: p < 0.0001; P, Percentile.
N eGFR_Schwartz_short eGFR_SchL eGFR_FAS_QA eGFR_FAS_QH eGFR_LM eGFR_LM_LBM UCC
Mean
± SD
% < 60 Mean
± SD
% < 60 Mean
±SD
% < 60 Mean
± SD
% < 60 Mean
±SD
% < 60 Mean
±SD
% < 60 N Mean
±SD
All patients 36,782 102.8
± 24.1
1.7 95.2
± 21.3
2.7 108.2
± 23.9
1.5 110.4
± 26.0
1.4 95.3
± 16.0
1.4 105.0
± 15.0
0.7 549 122.3
± 35.6
Sex
Female 17,146 ***
107.0
± 24.2
1.4 95.1
± 21.5
2.9 ***
108.9
± 24.4
1.6 ***
109.6
±25.3
1.6 ***
88.1
±11.9
1.9 104.9
± 14.1
0.6 263 123.1
±31.7
Male 19,636 99.2
± 23.3
1.9 95.3
± 21.1
2.5 107.6
± 23.5
1.4 111.1
± 26.6
1.3 101.7
± 16.4
1.0 105.1
± 15.6
0.7 286 121.6
±38.9
Age (yrs)
1–<6 1,849
114.2
± 33.1
4.6
101.5
± 29.5
7.6
100.5
± 29.3
8.1
103.0
± 30.0
6.9
93.4
± 17.6
3.6
108.3
± 13.6
0.5 27 144.5
±56.8
6–<12 7,879
111.0
± 24.7
1.7
98.6
± 22.0
3.4
102.9
± 23.2
2.7
106.0
± 23.8
2.3
101.7
± 16.7
1.2
105.8
± 13.4
0.7 92 125.1
± 36.3
12–<18 27,054
99.7
± 22.3
1.4
93.8
± 20.2
2.1
110.2
± 23.4
0.7
112.2
± 26.1
0.8 93.6
± 15.2
1.3
104.6
± 15.4
0.7 430 120.3
± 33.3
BMI
<P 90 31,553 102.7
± 24.0
1.7 95.3
± 21.3
2.7 108.1
± 24.0
1.5 110.4
± 26.0
1.5
95.6
± 16.1
1.4
103.8
± 14.4
0.7 481 121.9
± 35.3
≥P90–97 3,881 103.2
± 23.9
1.3 94.8
± 21.0
2.3 108.0
± 23.7
1.3 110.1
± 25.8
1.0
93.5
± 15.3
1.4
111.0
± 15.4
0.4 51 126.7
± 39.2
≥P97 1,346 103.9
± 24.7
1.6 96.0
± 21.7
2.7 109.2
± 25.1
1.9 111.3
± 26.3
1.6 94.6
± 15.5
1.6
116.1
± 17.2
0.5 17 120.8
± 34.3
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FIGURE 1 | (A) eGFR (36,780 patients) calculated by different formulae for
three age groups. Estimates (± standard error) are derived from linear
regression models adjusted for age, sex, diabetes duration, and BMI. ***p <
0.0001. (B) eGFR (27,744 patients) sorted into two groups by the
characteristic “microalbuminuria” or “no microalbuminuria,” respectively.
Estimates (± standard error) are derived from linear regression models,
adjusted for age, sex, diabetes duration, BMI, HbA1c, antihypertensive
medication. ***p < 0.0001.
TABLE 3 | Spearman correlation coefficients for eGFR and UCC, all patients, and
age groups.
UCC
N = 549
UCC age
< 6 yrs
N = 27
UCC age
6–<12 yrs
N = 92
UCC age
12–<18 yrs
N = 271
eGFR_Schwartz_short 0.30*** 0.11 0.14 0.33***
eGFR_SchL 0.29*** 0.11 0.14 0.32***
eGFR_FAS_QA 0.27*** 0.09 0.19 0.32***
eGFR_FAS_QH 0.20*** 0.09 0.14 0.24***
eGFR_LM 0.25*** 0.01 0.16 0.28***
eGFR_LM_LBM 0.26*** 0.11 0.10 0.29***
***p < 0.0001.
revealed a significant association between microalbuminuria and
eGFR according to all six formulae (increased eGFR-values when
microalbuminuria present) (Figure 1B), whereas a diagnosis did
not take effect in any formula.
eGFR in Correlation With UCC and With
Each Other
Using the Spearman correlation, Table 3 shows the relation
of eGFR (all formulae) and UCC. The maximal correlation
coefficient was 0.30 for eGFR_Schwartz_Short (all patients) and
0.33 also for eGFR_Schwartz_Short for the age group 12–<18
years. Figures 2A–F presents Bland-Altman-Plots (difference vs.
average) with regression line between UCC and all six formulae.
DISCUSSION
In our large paediatric population, the application of various
formulae for GFR estimation results in pretty far-flung values
(see Table 2). A similar or even greater variability is visible when
considering subgroups, e.g., sorted by age or BMI. These results
and the fact that so many formulae have been developed in
the first place visualises that the “ideal” eGFR-formula based on
serum creatinine might not exist. The Schwartz-short formula
was evaluated in children with chronic kidney disease (9). Indeed,
this formula was found to be reliable and accurate in children and
adolescents and in young adults with mild to moderate kidney
impairment (5), but not necessarily in other patient groups or
healthy children (17, 18). Hence, compared to median GFRs
of a meta-analysis looking into the measured GFR of children
and adolescents, and claiming that the data could be considered
as reference data (19), the eGFRs via Schwartz-short of our
cohort showed similar levels. The Schwartz-Lyon formula is the
further development of the Schwartz-short formula with the
intention to improve the performance by introducing two k-
coefficients. Due to the k-coefficient of 36.7 in the Schwartz-Lyon
formula (Schwartz-short: k = 41.3) for all patients but the males
>13 years of age (k = 41.3), we saw one of the lowest mean
eGFR-levels (generally and in the subgroups) of the study, and
lower levels compared to the levels of the meta-analysis-study
mentioned above (19). In 2012, the group around Pottel et al.
published “A simple height-independent equation for estimating
GFR in children” that was valid for Children aged < 14 years
(20). Quickly, this formula was refined by the FAS_QA- and
FAS_QH-formulae which pursued the goal to provide equations
for all ages, especially without the problematic discontinuity
between paediatric and adult equations (21). The principle
behind those new formulae were age- and sex-specific (median)
serum creatinine values, or height dependent values, respectively,
on the basis of a large Belgian data set of healthy subjects aged
0.1–20 years. Applying these two formulae to our cohort resulted
in a shift towards higher eGRF-values, generally and in almost all
subgroups with eGFR_FAS_QH > eGFR_FAS_QA-values. The
increase was especially accentuated for the male adolescents,
reflecting the effort to create formulae that meet the challenges
of non-linear serum creatinine rise above 14 years of age,
particularly in boys, and the large growth differences. The Lund-
Malmö (LM)- and Lund-Malmö-Lean-Body-mass (LM_LBM)-
formulae were originally designed for adults, and developed on
the basis of patients mostly with renal disease (12). In a second
step, the formulae were evaluated in a small group of children,
many of them again with suspected or confirmed renal disease
(22). The eGFR-values produced by the LM-formula, that takes
age and—via a constant factor—sex into account, were among
the lowest in our population. Compared to the meta-analysis
data of Pottel (19), we can assume an underestimation of GFR.
The introduction of the factor lean body mass by using the LM-
LBM-formula resulted in higher values with the highest values in
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FIGURE 2 | (A–F) Bland-Altman-Plots (plot of differences) between eGFR (A: eGFR_Schwartz_Short; B: eGFR_Schw_L; C: eGFR_FAS_QA; D: eGFR_FAS_QH; E:
eGFR_LM; F: eGFR_LM_LBM) and UCC with red regression line.
the group BMI ≥ P97—reflecting the newly included parameters
weight and height.
At a GFR threshold of < 60 mL/min/1.73 m2, approximately
50% of an adult’s normal kidney function is lost. This cut-off is
widely used for the definition of chronic kidney disease in adults
and in children aged > 2 years and adolescents (23), although
there is data that a threshold of <75 mL/min/1.73 m2 could
be more accurate in children (24). The range of eGFR-values
considered to be definitively pathological (<60 mL/min/1.73
m2) varied between 0.4% (eGFR_LM_LBM, subgroup BMI
≥P90–97) and 8.0% (eGFR_FAS_QA, subgroup age 1–<6 years)
in our study, with the age group 1–< 6 years showing the
highest percentages of pathological eGFRs over all formulae.
We would expect the youngest of the patients with type
1 diabetes (with the lowest mean duration of diabetes) to
be those with the least pathological values. A Belgian 2015-
study used the FAS-QA-formula in 8,505 subjects aged 2–25
years who were registered in a large hospital database and
assumedly in good renal health. This study reported eGFR-
values <60 mL/min/1.73 m2 in the age group 2–6 with a
maximal frequency of 0.65% (24). The FAS-QA-formula is
height independent, that leaves two possibilities to explain
the discrepancy (and the clear GFR underestimation): either a
variation in the serum creatinine values. This seems very unlikely
as all our study centres employed IDMS-traceable creatinine
measurements, as the dataset originally used for the FAS-QA-
formula. Alternatively, the Q-values (median of serum creatinine
of the Belgian population the formula was developed in) might
not be suitable for our German-Austrian-Swiss-Luxembourgish
population in that age group. Generally spoken, we have to be
aware, that differences among formulae using the same filtration
markers (here: creatinine) mirror differences in the variables
included in the equations and the forms and coefficients of the
variables. The variables are chosen and adapted to the population
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the formulae were developed and elaborated in. We have to
think carefully whether e.g., Schwartz-Short-formula (developed
in a chronic-kidney disease population) or FAS-QH-formula
(developed in healthy European children and adolescents) in
which age group might be more suitable to estimate GFR in a
population of children and adolescents with type 1 diabetes—
alternatives to the “classical” paediatric Schwartz-short-formula
are available.
What factors could be identified as influencing our eGFR-
values in regression analyses? Age and sex were significant
influencing factors for all (age) or almost all (sex) eGFR values,
but not always in the same direction: Schwartz-short, Schwartz-
Lyon, and Lund-Malmö-LBM formulae showed the younger the
higher eGFR-values whereas the “FAS-family” exhibited the older
the higher eGFR-values. Using Schwartz-short- and FAS-QA-
Formula meant higher eGFR-values in females than in males.
For FAS-QH, Lund-Malmö- and Lund-Malmö-LBM-formulae
the contrary was true. It is recognized that between the age
of 1 and 2 years (measured) GFR (scaled for Body Surface
Area BSA) reaches adult levels (18, 25, 26). However, serum
creatinine levels that serve as a basis for estimating GFR change
during growth mainly due to accretion of muscle, especially
in boys, until adolescence (27). Based on the assumption of a
more close linkage of muscle mass and height as opposed to
weight or BSA (28), the Schwartz-short- and Schwartz-Lyon-
formula introduced height into the equation. As the original
population for the Schwartz-formula were children with chronic
kidney disease with possible short stature, this formula possibly
underestimates GFR in adolescence. Schwartz-Lyon tries to
compensate for the factor (male) sex via a different k-coefficient
for boys. The “FAS-family”-approach consisted of the use of
population normalized (age related) Q-values, based on median
serum creatinine values. In a further step the FAS-formula
was modified by including age (FAS-QA) or height (FAS-QH)
and gender in a sophisticated way—but still leaves us with
age as an influencing factor as shown in our results. For the
factor sex, we have to keep in mind, that despite all attempts
to correct for sex in direct (Schwartz-Lyon-, FAS-QA-, Lund-
Malmö-formula) or indirect (Schwartz-short-, FAS-QH, Lund-
Malmö-LBM-formula) ways, we still can see an influence on the
eGFR-values for most formulae.
Diabetes duration seemed to be another influencing factor
for five formulae except FAS-QH-formula. The differences in
absolute numbers though between the group “diabetes duration
< 2 years” compared to “diabetes duration ≥ 2 years” were
marginal, and the direction inconsistent so that this significance
might be only due to large numbers.
Albuminuria is still seen as a biomarker of renal damage in
patients with diabetes, although no longer necessarily believed
to be the initial manifestation of chronic kidney disease (29).
The percentage of patients with microalbuminuria in our study
was comparable to other studies in paediatric T1D populations
(30, 31). Regression models showed a significant association
between microalbuminuria and eGFR-value in all formulae:
patients with microalbuminuria had significantly higher eGFR
values than those without microalbuminuria. Literature tells
us, that a high (measured) GFR in the means of glomerular
hyperfiltration may precede microalbuminuria (30, 32, 33) as a
sign of diabetic nephropathy, and that a high eGFR is associated
with a more rapid loss of kidney function (34). However,
the link between hyperfiltration and subsequent albuminuria
or eGFR loss in humans has not been consistently confirmed
(35). A study of Perrin et al. even stated, that eGFR cannot
accurately replace measured GFR to detect hyperfiltration (36).
Nevertheless, we think that our findings are indicative for a
possible renal impairment. Patients with increasing eGFR and
microalbuminuria should be carefully monitored.
In clinical practice, GFR in children is often measured by
creatinine clearance, relating serum creatinine levels to timed
urinary creatinine excretion. This method is substantially
less invasive than e.g., inulin clearance and therefore still
in use although it is not the most accurate method and
overestimates inulin clearance (37). One of the method’s
limitations is incomplete urine collection. The urine collection
of the 549 children include in our study took mainly place
during hospitalisations, for example in the course of initiation
pump therapy. Therefore, we can assume accurate and complete
collections under supervision of trained personnel. Another limit
particularly for our study is the small number of patients with
UCC compared to the number of patients where eGFR
could be calculated. But the UCC-population could be
considered as a representative sample of the total study-
population as there were no significant differences concerning
age, diabetes duration, HbA1c, BMI, serum-creatinine or
retinopathy/microalbuminuria rate. For all patients, the
eGFR_Schwartz_short-formula showed the highest correlation
(correlation coefficient 0.30) between eGFR-values and UCC the
lowest (0.20) the eGFR_FAS_QH-formula. Although there is a
positive correlation between UCC and eGFR-values determined
with different formulae, correlation is not good at all. Obviously
UCC and our “paediatric” eGFR-values are two different things,
despite the fact that both methods are based on creatinine. This
is in contrast to a large study in young adult T1D patients that
investigated the correlation between UCC and eGFR, but used
“adult” formulae (38).
The Bland-Altman-Plots describe the agreement between
UCC- and eGFR-values (difference against average). Ideally, all
the differences would be equal to zero, and the regression line
would be horizontal (39). This is not the case in our study. In
all six formulae, the differences that equal zero are scarce, and
clustered around “normal” values (75–110 ml/min/1.73 m2); the
higher the average, the higher the negative difference, resulting in
a skewed regression line. We interpret this finding that eGFR is
rather suitable for detecting low eGFR values and less for higher
values as the case may be in the state of hyperfiltration (>130
ml/min/1.73 m2). Hyperfiltration is a common phenomenon in
T1D, especially in early diabetes and as a possible sign of (future)
renal damage (40). A Swedish study in children and young adults
with T1D showed similar results: they measured GFR by inulin
clearance, and calculated eGFR using different formulae, but had
to state that eGFR does not reliably detect hyperfiltration (36).
Unfortunately non-creatinine endogenous biomarker values
(e.g., cystatin c, β-trace protein or β2-microglobulin) as an
alternative to the urinary creatinine clearance method were
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not available for our population. The same is true for data
on clearances with exogenous filtration markers, which are
considered as gold standard in the assessment of renal clearance
function. Such data would have been ideal for comparison with
the GFR-values estimated by various formulae. The lack of those
can be considered as a true limitation. But due to the “real-
life” conditions of the study we were fortunate to have over 500
urinary creatinine clearances, keeping in mind that the purpose
of those was screening children/adolescents with type 1 diabetes
for renal disease.
CONCLUSION
Our study showed that application of different formulae for
estimating GFR in a large population of T1D children and
adolescents leads to a broad range of eGFR values. The
population each formula was developed for has to be kept
in mind. None of the formulae seems to be perfect over all
subgroups we analysed. Despite attempts to take into account
e.g., age and sex and integrate those factors in a number
of ways, age and sex are anyhow recognised as influencing
factors on eGFR in regression analyses. Correlations between
measured UCC and eGFR were poor, and Bland-Altman-plots
revealed poor agreement between the two methods, especially
for eGFR values in the hyperfiltration range. We conclude,
that eGRF-calculations in children and adolescents with T1D
have to be regarded with extremely cautious attitude and—if
in doubt—have to be replaced by measured GFR, for example
inulin clearance.
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation, to any
qualified researcher.
ETHICS STATEMENT
The studies involving human participants were reviewed
and approved by Institutional review board of Ulm
University. Written informed consent to participate in this
study was provided by the participants’ legal guardian/next
of kin.
AUTHOR CONTRIBUTIONS
CB, ST, and RH contributed substantially to the conception and
design of the work as well as to the analysis and interpretation
of data for the work. CB drafted the manuscript. All authors
are responsible for data acquisition for the work, revised it
critically for important intellectual content, provided approval
for publication of the content, and agree to be accountable for
all aspects of the work in ensuring that questions related to the
accuracy or integrity of any part of the work are appropriately
investigated and resolved.
ACKNOWLEDGMENTS
The authors thank all German, Austrian, Swiss, and
Luxembourgish diabetes centres participating in the DPV
initiative (see Supplementary Material), A. Hungele, Institute of
Epidemiology and Medical Biometry, University of Ulm, Ulm,
Germany for the contribution to the development of the DPV
documentation software and data handling, and A. C. Sewell,
Ingelheim amMain, Germany for proof-reading the manuscript.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fendo.
2020.00052/full#supplementary-material
REFERENCES
1. Li L, Jick S, Breitenstein S, Michel A. Prevalence of diabetes and diabetic
nephropathy in a large U.S. commercially insured pediatric population, 2002–
2013. Diabetes Care. (2016) 39:278–84. doi: 10.2337/dc15-1710
2. Narres M, Claessen H, Droste S, Kvitkina T, Koch M, Kuss O, et al. The
incidence of end-stage renal disease in the diabetic (compared to the non-
diabetic) population: a systematic review. PLoS ONE. (2016) 11:e0147329.
doi: 10.1371/journal.pone.0147329
3. American Diabetes Association. 3. Comprehensive medical evaluation and
assessment of comorbidities: standards of medical care in diabetes – 2018.
Diabetes Care. (2018) 41(suppl 1):28–37. doi: 10.2337/dc18-S003
4. Stevens PE, Levin A. Evaluation and management of chronic kidney
disease: synopsis of the kidney disease: improving global outcomes
2012 clinical practice guideline. Ann Intern Med. (2013) 158:825–30.
doi: 10.7326/0003-4819-158-11-201306040-00007
5. Selistre L, Rabillou M, Cochat P, de Souza V, Iwaz J, Lemoine S,
et al. Comparison of the Schwartz and CKD-EPI equations for
estimating glomerular filtration rate in children, adolescents and adults:
a retrospective cross-sectional study. PLoS Med. (2016) 13:e1001979.
doi: 10.1371/journal.pmed.1001979
6. Azzi A, Cachat F, Faouzi M, Mosig D, Ramseyer P, Girardin E, et al. Is there an
age cutoff to apply adult formulas for GFR estimation in children? J Nephrol.
(2015) 28:59–66. doi: 10.1007/s40620-014-0148-y
7. Chehade H, Girardin E, Iglesias K, Ramseyer P, Frey P, Bardy D, et al.
Assessment of adult formulas for glomerular filtration rate estimation in
children. Pediatr Nephrol. (2013) 28:105–14. doi: 10.1007/s00467-012-2298-2
8. Zachwieja K, Korohoda P, Kwinta-Rybicka J, Miklaszewska M, Moczulska
A, Bugajska J, et al. Which equations should and which should not be
employed in calculating eGFR in Children? Adv Med Sci. (2015) 60:31–40.
doi: 10.1016/j.advms.2014.08.007
9. Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al.
New equations to estimate GFR in children with CKD. J Am Soc Nephrol.
(2009) 20:629–37. doi: 10.1681/ASN.2008030287
10. De Souza VC, Rabilloud M, Cochat P, Selistre L, Hadj-Aissa A,
Kassai B, et al. Schwartz formula: is one k-coefficient adequate for
all children? PLoS ONE. (2012) 7:e53439. doi: 10.1371/journal.pone.00
53439
11. Hoste L, Dubourg L, Selistre L, De Souza VC, Ranchin B, Hadj-Aïssa, P,
et al. A new equation to estimate the glomerular filtration rate in children,
adolescents and young adults. Nephrol Dial Transplant. (2014) 29:1082–91.
doi: 10.1093/ndt/gft277
Frontiers in Endocrinology | www.frontiersin.org 8 February 2020 | Volume 11 | Article 52
Boettcher et al. eGFR in Type-1-Diabetes Children
12. Björk S, Bäck S-E, Sterner G, Carlson J, Lindström V, Bakoush O,
et al. Prediction of relative glomerular filtration rate in adults: new
improved equation based on Swedish Caucasians and standardized
plasma-creatinine assays. Scand J Clin Lab Invest. (2007) 67:678–95.
doi: 10.1080/00365510701326891
13. Neuhauser H, Schienkiewitz A, Schaffrath Rosario A, Dortschy R, Kurth B.
Beiträge zur Gesundheitsberichterstattung des Bundes. Referenzperzentile für
anthropometrische Maßzahlen und Blutdruck aus der Studie zur Gesundheit
von Kindern und Jugendlichen in Deutschland (KiGGS). 2nd ed. Berlin: Robert-
Koch-Institut (2013).
14. Neuhauser HK, Thamm M, Eller U, Hense HW, Schaffrath Rosario
A. Blood pressure percentiles by age and height from nonoverweight
children and adolescents in Germany. Pediatrics. (2011) 127:e978–88.
doi: 10.1542/peds.2010-1290
15. The Diabetes Control and Complications Trial Research Group. The effect of
intensive treatment of diabetes on the development and progression of long-
term complications in insulin-dependent diabetes mellitus. N Engl J Med.
(1993) 329:977–86. doi: 10.1056/NEJM199309303291401
16. Doolan PD, Alpen EL, Theil GB. A clinical appraisal of the plasma
concentration and endogenous clearance of creatinine. Am J Med. (1962)
32:65–79. doi: 10.1016/0002-9343(62)90183-3
17. Fadrowski JJ, Neu AM, Schwartz GJ, Furth SL. Pediatric GFR estimating
equations applied to adolescents in the general populations. Clin J Am Soc
Nephrol. (2011) 6:1427–35. doi: 10.2215/CJN.06460710
18. Pottel H, Mottaghy FM, Zaman Z, Martens F. On the relationship between
glomerular filtration rate and serum creatinine in children. Pediatr Nephrol.
(2010) 25:927–34. doi: 10.1007/s00467-009-1389-1
19. Pottel H. Measuring and estimating glomerular filtration rate in children.
Pediatr Nephrol. (2017) 32:249–63. doi: 10.1007/s00467-016-3373-x
20. Pottel H, Hoste L, Matrtens F. A simple height-independent equation for
estimating glomerular filtration rate in children. Pediatr Nephrol. (2012)
27:973–9. doi: 10.1007/s00467-011-2081-9
21. Pottel H, Hoste L, Dubourg L, Ebert N, Schaeffner E, Eriksen BO, et al. An
estimated glomerular filtration rate equation for the full age spectrum. Nephrol
Dial Transplant. (2016) 31:789–806. doi: 10.1093/ndt/gfv454
22. Nyman U, Björk J, Lindstöm V, Grubb A. The Lund-Malmö creatinine-
based glomerular filtration rate prediction equation for adults also
performs well in children. Scand J Clin Lab Invest. (2008) 68:568–76.
doi: 10.1080/00365510801915163
23. KDIGO CKD Work Group. KDIGO 2012 clinical practice guideline for the
evaluation and management of chronic kidney disease . Kidney Int. (2013)
Suppl 3:1–150.
24. Pottel H, Hoste L, Delanaye P. Abnormal glomerular filtration rate in children,
adolescents and young adults starts below 75 mL/min/1.73 m2. Pediatr
Nephrol. (2015) 30:821–8. doi: 10.1007/s00467-014-3002-5
25. Brodehl J, Gelissen K,Weber HP. Postnatal development of tubular phosphate
reabsorption. Clin Nephrol. (1982) 17:163–71.
26. Piepsz A, Tondeur M, Ham H. Revisiting normal 51Cr-
ethylenediaminetetraacetic acid clearance values in children. Eur J
Nucl Med Mol Imaging. (2006) 33:1477–82. doi: 10.1007/s00259-006-
0179-2
27. Bökenkamp A, Domanetzki M, Zinck R, Schumann G, Brodehl J. Reference
values for cystatin C serum concentration in children. Pediatr Nephrol. (1998)
12:125–9. doi: 10.1007/s004670050419
28. Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A. A simple estimate of
glomerular filtration rate in children derived from body length and plasma
creatinine. Pediatrics. (1976) 58:259–63.
29. Krolewski AS. Progressive renal decline: the new paradigm of diabetic
nephropathy in type 1 diabetes. Diabetes Care. (2015) 38:954–62.
doi: 10.2337/dc15-0184
30. Amin R, Turner C, van Aken S, Bahu TK, Watts A, Lindsell DR,
et al. The relationship between microalbuminuria and glomerular filtration
rate in young type 1 diabetic subjects: the oxford regional prospective
study. Kidney Int. (2005) 68:1740–9. doi: 10.1111/j.1523-1755.2005.0
0590.x
31. Raile K, Galler A, Hofer S, Dunstheimer D, Busch P, Holl RW. Diabetic
nephropathy in 27,805 children, adolescents, and adults with type 1 diabetes.
Diabetes Care. (2007) 30:2523–8. doi: 10.2337/dc07-0282
32. Dahlquist G, Stattin EL, Rudberg S. Urinary albumin excretion rate and
glomerular filtration rate in the prediction of diabetic nephropathy; a
long-term follow-up study of childhood onset type-1 diabetic patients.
Nephol Dial Transplant. (2001) 16:1382–86. doi: 10.1093/ndt/16.
7.1382
33. Jerums G, Premaratne E, Panagiotopoulos S, MacIsaac RJ. The clinical
significance of hyperfiltration in diabetes. Diabetolgia. (2010) 53:2093–104.
doi: 10.1007/s00125-010-1794-9
34. Schwandt A, Bergis D, Denkinger M, Gollisch KSC, Sandig D,
Stingl H, et al. Risk factors for decline in renal function among
young adults with type 1 diabetes. J Diab Complic. (2018) 32:940–6.
doi: 10.1016/j.jdiacomp.2018.07.007
35. Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Fogarty DG.
Is hyperfiltration associated with the future risk of developing
diabetic nephropathy? A meta-analysis. Diabetologia. (2009) 52:691–7.
doi: 10.1007/s00125-009-1268-0
36. Perrin NES, Berg UB. Estimated glomerular filtration rates
cannot replace measured GFR in type 1 diabetes patients with
hyperfiltration. Acta Paediatr. (2015) 104:730–7. doi: 10.1111/apa.
12993
37. Soveri I, Berg UB, Björk J, Elinder CG, Grubb A, Mejare I, et al.
Measuring GFR: a systematic review. Am J Kidney Dis. (2014) 64:411–24.
doi: 10.1053/j.ajkd.2014.04.010
38. Schwandt A, Denkinger M, Fasching P, Pfeifer M, Wagner C, Weiland J,
et al. Comparison of MDRD, CKD-EPI, and Cockcroft-Gault equation in
relation to measured glomerular filtration rage among a large cohort with
diabetes. J Diab Complic. (2017) 31:1376–83. doi: 10.1016/j.jdiacomp.2017.
06.016
39. Giavarina D. Understanding Bland Altman analysis. Biochem Med. (2015)
25:141–51. doi: 10.11613/BM.2015.015
40. Tonneijck L, Muskiet MHA, Smits MM. Glomerular hyperfiltration
in diabetes: mechanisms, clinical significance and treatment. J
Am Soc Nephrol. (2017) 28:1023–39. doi: 10.1681/ASN.20160
60666
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Boettcher, Utsch, Galler, Grasemann, Borkenstein, Denzer,
Heidtmann, Tittel and Holl. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) and
the copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Endocrinology | www.frontiersin.org 9 February 2020 | Volume 11 | Article 52
